JPRN-jRCTs051180139已完成未知
Examination for Cardiac function Effect by Echocardiography in Diabetes with chronic heart failure. - EXCEED
RAKUGI HIROMI0 个研究点目标入组 129 人开始时间: 2019年3月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 129
研究概览
简要总结
We conducted six months of RCT of ipragliflozin versus conventional treatment in 68 older T2D patients with heart failure with preserved ejection fraction. There was no significant improvement in diastolic function, echocardiographic measurements, plasma NT-proBNP levels, NYHA classification, HbA1c, or blood pressure in the ipragliflozin group compared with the conventional treatment group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Type 2 diabetes patients with NT-proBNP> 125 pg / mL or BNP> 40 pg / mL and chronic heart failure (NYHA function classification I - III)
- •1.Within the last 3 months,not administered the SGLT2 inhibitor.
- •2.Aged < 65years:HbA1c 7%<=and < 10%
- •,Aged >= 65years:HbA1c 7.5%<= and < 10%.
- •3.Aged >= 20 and < 75years.
- •4.Outpatient.
- •5.Any gender.
- •6.Provision of written consent.
排除标准
- •1.Acute exacerbation patients with chronic heart failure.
- •2.Within 3months, stroke, Acute coronary syndrome ,and percutaneous coronary angioplasty, coronary artery bypass surgery.
- •3.LVEF<50% and Severe valvular disease.
- •4.Concurrent Atrial fibrillation.
- •5.Severe liver dysfunction (Chronic hepatitis C etc).
- •6.Severe Kidney failure or eGFR <30mL/min/1.73m2
- •7.Concurrent malignancy.
- •8.Concurrent dementia.
- •9.State requiring nursing care.
- •10.Pregnancy or possible pregnancy.
- •11.SGLT2 inhibitors medicine contraindications.
- •12.Inappropriateness as a subject of this trial as determined by the investigator.
研究者
相似试验
招募中
2 期
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKDChronic Kidney DiseasesNCT05359263Tor Biering-Sørensen222
已完成
3 期
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)Type 2 Diabetes MellitusNCT01986881Merck Sharp & Dohme LLC8,246
已完成
2 期
Dapagliflozin (DAPA) Effects in HFpEFHeart Failure With Preserved Ejection FractionNCT04730947Mayo Clinic38
招募中
2 期
Ertugliflozin in Chronic Heart FailureHeart FailureNCT04438213Yale University60
已完成
不适用
Does dapagliflozin change heart function as detected by ultrasound in patients with heart failure?Heart failure and reduced ejection fractionCirculatory SystemISRCTN95382621Mouloud Mammeri University of Tizi-Ouzou43